Structural proteomics in drug discovery.
High-throughput, automated or semiautomated methodologies implemented by companies and structural genomics initiatives have accelerated the process of acquiring structural information for proteins via x-ray crystallography. This has enabled the application of structure-based drug design technologies to a variety of new structures that have potential pharmacologic relevance. Although there remain major challenges to applying these approaches more broadly to all classes of drug discovery targets, clearly the continued development and implementation of these structure-based drug design methodologies by the scientific community at large will help to address and provide solutions to these hurdles. The result will be a growing number of protein structures of important pharmacologic targets that will help to streamline the process of identification and optimization of lead compounds for drug development. These lead agonist and antagonist pharmacophores should, in turn, help to alleviate one of the current critical bottlenecks in the drug discovery process; that is, defining the functional relevance of potential novel targets to disease modification. The prospect of generating an increasing number of potential drug candidates will serve to highlight perhaps the most significant future bottleneck for drug development, the cost and complexity of the drug approval process.
Tari
Leslie W
LW
ActiveSight, 4045 Sorrento Valley Blvd, San Diego, CA 92121, USA. ltari@active-sight.com
Rosenberg
Martin
M
Schryvers
Anthony B
AB
D000818:Animals; D018360:Crystallography, X-Ray; D015195:Drug Design; D015870:Gene Expression; D006801:Humans; D046912:Multiprotein Complexes; D011506:Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*
D046912:Multiprotein Complexes; D011506:Proteins